6 million), compared with Rs 236 crore a 12 months earlier. GlaxoSmithKline, which derives a lot of its income from India, continued to grapple with worries pursuing the inclusion of its key products and solutions including Ceftum antibiotic and T-Bact ointment from the nation’s Nationwide Lis